Richard Prins Sells 4,179 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard Prins sold 4,179 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the transaction, the director directly owned 35,183 shares in the company, valued at $953,459.30. This represents a 10.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH traded up $0.98 during trading hours on Tuesday, hitting $27.69. 375,501 shares of the stock were exchanged, compared to its average volume of 536,484. The firm’s fifty day moving average price is $25.62 and its 200 day moving average price is $25.46. Amphastar Pharmaceuticals, Inc. has a 52-week low of $20.39 and a 52-week high of $46.11. The company has a market cap of $1.27 billion, a P/E ratio of 10.37 and a beta of 0.77. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.10. Amphastar Pharmaceuticals had a return on equity of 20.76% and a net margin of 18.64%.The firm had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. As a group, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current fiscal year.

Analysts Set New Price Targets

AMPH has been the topic of several research reports. Needham & Company LLC decreased their price target on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Bank of America upped their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 26th. Zacks Research lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $31.20.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. raised its position in Amphastar Pharmaceuticals by 27.9% in the first quarter. Victory Capital Management Inc. now owns 81,087 shares of the company’s stock valued at $2,351,000 after purchasing an additional 17,700 shares during the period. IFP Advisors Inc acquired a new position in Amphastar Pharmaceuticals during the 1st quarter worth about $34,000. TD Asset Management Inc boosted its holdings in Amphastar Pharmaceuticals by 20.2% during the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock valued at $64,130,000 after acquiring an additional 371,856 shares during the period. Picton Mahoney Asset Management grew its position in Amphastar Pharmaceuticals by 6,600.0% in the 1st quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company’s stock valued at $46,000 after acquiring an additional 1,584 shares in the last quarter. Finally, GSA Capital Partners LLP increased its stake in Amphastar Pharmaceuticals by 159.8% during the first quarter. GSA Capital Partners LLP now owns 45,297 shares of the company’s stock worth $1,313,000 after purchasing an additional 27,863 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.